(IN BRIEF) Roche has announced that the US FDA has accepted its supplemental Biologics License Application for Lunsumio VELO, a subcutaneous formulation of mosunetuzumab, in combination with Polivy for adults with relapsed or refractory large B-cell lymphoma, including diffuse large … Read the full press release
Posted in Business, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged antibody-drug conjugate, ASCO Annual Meeting, Basel, CD20xCD3 bispecific antibody, CD79b, CELESTIMO, chemotherapy-free regimen, community oncology, crs, cytokine release syndrome, diffuse large B-cell lymphoma, DLBCL, European Hematology Association Congress, FDA, FDA Filing Acceptance Brings Roche’s Chemotherapy-Free Lymphoma Combination Closer to Potential Approval, follicular lymphoma, gemcitabine, haematology, LBCL, Levi Garraway, Lunsumio, Lunsumio VELO, Lunsumio VELO and Polivy Combination Shows 59 Percent Risk Reduction in Roche’s FDA Filing for LBCL, lymphoma care, Lymphoma Research Foundation, MabThera®, Meghan Gutierrez, Mission Cancer and Blood, MorningLyte, mosunetuzumab, Non-Hodgkin lymphoma, outpatient-ready treatment, oxaliplatin, PFS, Phase III Trial, polatuzumab vedotin, Polivy, progression-free survival, R-GemOx, relapsed or refractory large B-cell lymphoma, Rituxan, rituximab, Roche, Roche Reports FDA Acceptance of sBLA Based on SUNMO Study Results in Relapsed or Refractory Large B-Cell Lymphoma, sBLA, SUNMO study, supplemental Biologics License Application, Switzerland, T-cell engaging bispecific antibody, Tara M Graff
(IN BRIEF) Roche has received FDA acceptance under Priority Review for its New Drug Application for giredestrant as an adjuvant treatment for adults with ER-positive, HER2-negative stage I-III breast cancer. The FDA is expected to decide on the application by … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged adjuvant treatment, American Society of Clinical Oncology Congress, ASCO 2026, Basel, breast cancer research, CDK4/6 inhibitor, early stage breast cancer, endocrine therapy, ER-positive breast cancer, ESR1-mutated breast cancer, evERA Breast Cancer, everolimus, FDA, FDA Accepts Roche’s Giredestrant Application as Potential New Adjuvant Treatment for Early-Stage Breast Cancer, FDA Sets November 2026 Decision Date for Roche’s Giredestrant in Early-Stage ER-Positive Breast Cancer, giredestrant, HER2-negative breast cancer, hyaluronidase, iDFS, invasive disease-free survival, Levi Garraway, lidERA Breast Cancer, NDA, New Drug Application, oncology, overall survival, Palbociclib, PDUFA, pertuzumab, Phesgo, Prescription Drug User Fee Act, Priority Review, Roche, Roche Moves Forward With Giredestrant Filing in Curative-Intent Breast Cancer Treatment Setting, Roche Secures FDA Priority Review for Giredestrant in Early-Stage ER-Positive Breast Cancer, selective oestrogen receptor degrader, SERD, stage I breast cancer, stage II breast cancer, stage III breast cancer, targeted therapy, trastuzumab, United States Food and Drug Administration
(IN BRIEF) Novartis will present 31 abstracts across its immunology portfolio at EULAR 2026 in London, highlighting new data for Cosentyx, ianalumab and rap-cel in several high-burden autoimmune diseases. Key presentations include results from REPLENISH, the largest global Phase III … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Marketing, Pharma & Biotech, Switzerland
Tagged Angelika Jahreis, AUTOGRAPH-IIM, AUTOGRAPH-SSC, autoimmune diseases, Basel, biologics, CAR-T cell therapy, CD19-directed therapy, clinical data, Cosentyx, EULAR 2026, European Alliance of Associations for Rheumatology, FUTURE 1, FUTURE 5, ianalumab, Ianalumab and Rap-Cel Data Across Rheumatology and Autoimmune Disease Research, idiopathic inflammatory myopathies, immunology, June 2026, London, NEPTUNUS-1, NEPTUNUS-2, Novartis, Novartis Advances Immunology Pipeline with 31 Abstracts Accepted for EULAR 2026 Congress in London, Novartis Highlights New Cosentyx, Novartis to Share Phase III and CAR-T Therapy Data Supporting Momentum in Complex Autoimmune Diseases, Phase II Study, Phase III Trial, polymyalgia rheumatica, psoriatic arthritis, rap-cel, rapcabtagene autoleucel, REPLENISH trial, rheumatology, secukinumab, Sjögren’s disease, systemic lupus erythematosus, systemic sclerosis, VAY736, YTB323
(IN BRIEF) Novartis will present data from 15 abstracts across its kidney disease portfolio at the European Renal Association Congress 2026 in Glasgow from June 3 to 6. The presentations include late-breaking Phase III data for Vanrafia® from the ALIGN … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Marketing, Pharma & Biotech, Switzerland
Tagged 124-week data, ADPKD, ALIGN trial, anti-APRIL therapy, anti-miR-17 oligonucleotide, APPLAUSE-IgAN, APPRISE-C3G, atrasentan, autosomal dominant polycystic kidney disease, Basel, C3 glomerulopathy, C3G, C3G and ADPKD Data at European Renal Association Congress, cardiovascular renal and metabolic development, dialysis, EGFR, ERA 2026, European Renal Association Congress, Fabhalta, farabursen, Glasgow, IgA nephropathy, IgAN, IgNITE, immune-mediated kidney diseases, iptacopan, June 2026, kidney care, kidney disease, kidney function, late-breaking data, Novartis, Novartis Advances Kidney Disease Research with New IgAN, Novartis Highlights Expanding Renal Pipeline and Disease Insights at ERA 2026 in Glasgow, Novartis Presents New Evidence Supporting Future Treatment Approaches in IgA Nephropathy and C3 Glomerulopathy, Novartis Strengthens Kidney Care Portfolio with New Scientific Data Across Progressive Immune-Mediated Renal Diseases, Novartis to Showcase Phase III Vanrafia and Fabhalta Data Alongside Long-Term Zigakibart Results at ERA 2026, phase I/II data, Phase III data, real-world evidence, renal disease, renal portfolio, Ruchira Glaser, transplantation, Vanrafia, zigakibart
(IN BRIEF) Kuehne+Nagel has signed a five-year agreement to become the Official Logistics Partner of MCH Group, supporting more than 150 events annually across major Swiss exhibition venues including Messe Basel, Messe Zurich, and Beaulieu Lausanne. The partnership covers international … Read the full press release
Posted in Art & Culture, Business, Germany, Industrial, International Trade, Management, News, Switzerland, Transportation & Logistics
Tagged Art Basel, Basel, Beaulieu Lausanne, convention centers, event logistics, event management, exhibition logistics, Exhibitions, expo logistics, Giardina, global logistics, international shipping, Joern Schneemann, Kuehne+Nagel, Kuehne+Nagel named Official Logistics Partner of MCH Group under new five-year agreement, Kuehne+Nagel Secures Five-Year Logistics Partnership With MCH Group, live marketing, logistics partnership, logistics services, MCH Group, MCH Group Selects Kuehne+Nagel to Manage Logistics for Major Swiss Exhibition Venues, Messe Basel, Messe Zurich, New Long-Term Partnership Expands Kuehne+Nagel’s Presence in Global Event Logistics Sector, Roman Imgrüth, Schindellegi, Supply Chain Management, Swiss events, Swissbau, Switzerland, Trade Fairs, Transportation Industry
(IN BRIEF) Roche announced that its Phase III INShore trial evaluating Gazyva/Gazyvaro (obinutuzumab) in children and young adults with idiopathic nephrotic syndrome met its primary endpoint, showing superior sustained remission rates at one year compared to mycophenolate mofetil (MMF). The … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged B cell targeting, Basel, Chronic kidney disease, corticosteroids, EMA, FDA, Gazyva, Gazyva/Gazyvaro Demonstrates Superior Sustained Remission in Children and Young Adults With Idiopathic Nephrotic Syndrome, Gazyvaro, idiopathic nephrotic syndrome, immune-mediated kidney diseases, INS, INShore study, Levi Garraway, lupus nephritis, NOBILITY study, obinutuzumab, pediatric nephrology, phase III clinical trial, proteinuria, REGENCY study, renal disease, Roche, Roche Announces Positive Phase III INShore Results for Gazyva/Gazyvaro in Children and Young Adults With Idiopathic Nephrotic Syndrome, sustained remission, targeted therapy
(IN BRIEF) Novartis will present new data from 27 abstracts at the 2025 American College of Rheumatology (ACR) Convergence, featuring late-breaking Phase III results from the NEPTUNUS-1 and NEPTUNUS-2 trials of ianalumab in Sjögren’s disease, which could become the first … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged ACR 2025, allergy, Angelika Jahreis, autoimmune diseases, Basel, biologics, biomarker research, CAR-T therapy, Cosentyx, Dermatology, EXPLORE44, Fortitude, HARBOR trial, ianalumab, immunology, NEPTUNUS trials, NEPTUNUS-1, NEPTUNUS-2, Novartis, Novartis Highlights Strong Immunology Pipeline with Positive Phase III Sjögren’s Results and CAR-T Data in Lupus at ACR 2025, Phase III data, psoriatic arthritis, rapcabtagene autoleucel, rheumatology, secukinumab, Sjögren’s disease, small molecules, systemic lupus erythematosus, YTB323
(IN BRIEF) Novartis announced a definitive agreement to acquire Avidity Biosciences for USD 12 billion in cash, in a move that strengthens its neuroscience franchise and accelerates its xRNA therapeutic strategy. The acquisition brings Avidity’s late-stage programs in myotonic dystrophy … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, Antibody Oligonucleotide Conjugates, AOCs, Avidity Biosciences, Basel, biopharma, biopharmaceutical innovation, biotechnology, clinical research, DM1, DMD, drug development, Duchenne muscular dystrophy, EXPLORE44 trial, facioscapulohumeral muscular dystrophy, FORTITUDE trial, FSHD, genetic medicine, HARBOR trial, muscle-directed therapy, myotonic dystrophy type 1, neuromuscular diseases, Novartis, Novartis Strengthens Neuroscience Franchise with Acquisition of Avidity Biosciences and Its Muscle-Directed RNA Platform, RNA delivery, RNA therapeutics, San Diego, SpinCo, Vas Narasimhan, xRNA strategy
(IN BRIEF) A new expert-led publication in the European Medical Journal, supported by Bayer, highlights the growing global burden of allergic rhinitis (hay fever) among children. Affecting 20% of children worldwide, the condition is linked to reduced academic performance, poor … Read the full press release
Posted in Education, Environment, Infrastructure & Utilities, News, Pharma & Biotech, Science, Society, Switzerland, Technology
Tagged academic performance, allergic rhinitis, allergy-friendly schools, antihistamines, ARIA guidelines, asthma prevention, Basel, Bayer, child wellbeing, children’s health, climate change, European Medical Journal, Experts Call for Urgent Action to Address the Growing Impact of Allergic Rhinitis on Children’s Health and Education, Experts Urge Global Action to Combat the Hidden Toll of Allergic Rhinitis on Children’s Education and Wellbeing, Gabriela Zuniga, global health, hay fever, indoor allergens, Lei Cheng, Mário Morais-Almeida, Michael Blaiss, non-sedating antihistamines, pediatric allergy, pollution, Ricardo Salazar, school environment, sleep disturbance, urbanization
(IN BRIEF) EQT Life Sciences has led a Series A investment in Mosanna Therapeutics to advance its lead drug candidate, MOS118—a nasal spray designed to treat obstructive sleep apnea—into Phase 2 trials. Co-investors include Pivotal bioVenture Partners, Forbion, Norwest, and … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Sweden, Switzerland, Technology
Tagged airway reflex restoration, Basel, biotech funding, Daniela Begolo, David Weber, EQT Life Sciences, Forbion, Forty51 Ventures, HTGF, MOS118, Mosanna Therapeutics, nasal spray therapy, neurological treatment, non-invasive sleep apnea therapy, Norwest, obstructive sleep apnea, OSA treatment, partnership, Phase 2 clinical trial, Pivotal bioVenture Partners, Redwood City, Supermoon Capital, sustainability
(IN BRIEF) Boehringer Ingelheim, via its subsidiary NBE Therapeutics, has launched a cutting-edge ADC research and development facility in Basel with a CHF 27 million investment. The center is a key part of the company’s strategic efforts to advance next-generation … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged ADC, Basel, Boehringer Ingelheim, Cancer Therapies, CHF 27 million, DGNB Certificate Gold, Jean Engela, Karl Penz, Kaspar Sutter, NBE Therapeutics, oncology research, Swiss biotech, Synaffix B.V., Vienna
(IN BRIEF) Syngenta has acquired Novartis’ natural products and genetic strains assets to enhance its biologicals research capabilities and support the agricultural sector’s transition to sustainability. This acquisition complements the opening of a state-of-the-art biologicals production facility in South Carolina … Read the full press release
Posted in Agriculture, Chemicals, Industrial, Investment, Switzerland
Tagged AI, analytics, Basel, bio-insecticides, biocontrols, bioengineering, biologicals, biologicals production facility, Biomolecular Chemistry team, biostimulants, Camilla Corsi, crop protection, data science, downstream processing, fermentation, genetic strains, Ginkgo Bioworks, Intrinsyx Bio, Jonathan Brown, Latin America, Lavie Bio, Lithos Crop Protect, natural products, North America, Novartis, Novartis Natural Products, nutrient efficiency, nutrient use efficiency, Orangeburg, pheromone solutions, Provivi, Regenerative Agriculture, research and development, Seedcare, soil health, South Carolina, Sustainability Priorities, sustainable farming practices, Switzerland, Syngenta, TraitSeq, Valagro
(IN BRIEF) ETH Zurich has opened a new research facility on Basel’s Schällemätteli life science campus, housing the Department of Biosystems Science and Engineering. The state-of-the-art building is designed to foster collaboration and innovation in experimental biology, bioinformatics, and bioengineering. … Read the full press release
Posted in Business, Education, Environment, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Science, Switzerland, Technology
Tagged Basel, Department of Biosystems Science and Engineering (BSS), ETH Zurich, High-Tech Research Facility, life sciences, partnership, sustainability, Sven Panke
(PRESS RELEASE) ZÜRICH, 8-Dec-2021 — /EuropaWire/ — Credit Suisse, a global wealth manager, investment bank and financial services firm, has announced the publication of its study on the Swiss office property market. The full report made in English and called … Read the full press release
Posted in Business, Financial, Investment, News, Real Estate, Switzerland
Tagged Basel, Credit Suisse, demand, economists, Geneva, home working, Immediate outlook mixed, Lausanne, office market, office property market, office renovations, office space, real estate, real estate economists, Switzerland, Zurich
(PRESS RELEASE) ZURICH, 13-Oct-2020 — /EuropaWire/ — Credit Suisse, a global wealth manager, investment bank and financial services firm, has announced the release of its Locational Quality Indicator annual study for 2020 that looks into the locational quality of Swiss … Read the full press release
Posted in Banks, Economy, Financial, Investment, News, Switzerland
Tagged Aargau, Basel, Bern, Canton Aargau, Canton Basel-Stadt, Canton Fribourg, Canton Geneva, Canton Lucerne, Canton Valais, Canton Zug, cantonal rankings, corporate income tax, corporate taxes, Credit Suisse, Graubünde, land, locational quality, Locational Quality Indicator, Nidwalden, Schaffhausen, Schwyz, Solothurn, Swiss cantons, Swiss labor force, Swiss regions, Ticino, transport accessibility, Vaud, Zurich
EMA, MHRA and FDA among regulatory agencies participating (PRESS RELEASE) BERLIN, 10-Jun-2019 — /EuropaWire/ — The Parenteral Drug Association (PDA) is excited to host its 4th Annual European Meeting: Global Healthcare of the Present and the Future, June 25-26 in … Read the full press release
Posted in France, Germany, Healthcare, Ireland, Media, Netherlands, News, Pharma & Biotech, Science, Switzerland, United Kingdom
Tagged 4th PDA European Annual Meeting, Amsterdam, automation, Basel, Berlin, biopharmaceuticals, data quality management, data science, digitalization, Dublin, EMA, European Medicines Agency, FDA, Felix G. Rebitschek, Healthcare, HPRA, London, Manufacturing, manufacturing technologies, Max Planck Institute, medicines, MHRA, Paris, PDA, pharmaceuticals, PIC/S, regulators, Virtual Reality, Walter Morris, WHO, Zurich
BASEL, Switzerland, 23-Aug-2017 — /EuropaWire/ — Global brand leader Invacare brings next generation technology to powerchairs, following extensive trials and consumer-led insights. Touch screen technology is used daily on devices such as smartphones and tablets and thanks to Invacare, this … Read the full press release
Posted in France, Germany, Healthcare, News, Society, Switzerland, Technology, United Kingdom
Tagged Adjustable brightness, Baden-Wuttemberg, Basel, Cardiff, controls, electric wheelchairs, Fondettes, Indre et Loire, Invacare, Invacare International Sarl, Isny im Allgau, left or right handed use, LINX, Pencoed, power wheelchairs, Powerchairs, REM400, remotes, Screen lock out function, swipe operation, tap operation, technology, touch screen, touch screen technology, touchscreen, Tours, wheelchair, Wheelchairs, Witterswil
BASEL, 22-10-2015 — /EuropaWire/ — To promote consistent implementation of the Basel III countercyclical capital buffer, the Basel Committee on Banking Supervision has issued frequently asked questions and other supporting information. The information published today includes a list of all … Read the full press release
Basel, 04-6-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the acquisition of Genia Technologies, Inc. (Genia), a privately held company, based in Mountain View, California, USA. Genia is developing a single-molecule, semiconductor based, DNA sequencing platform using nanopore … Read the full press release
Posted in Business, Management, Pharma & Biotech, Switzerland, Technology
Tagged Basel, Genia Technologies, nanopore technology, Roche, Roland Diggelmann, Stefan Roever
Investment to help meet rising demand for licensed biologics and expected pipeline growth Basel, Switzerland, 16-10-2013 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced plans to invest 800 million Swiss francs within its global manufacturing network to increase production … Read the full press release
Posted in Business, Germany, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged Basel, biologic medicines, Daniel O’Day, Germany, Kadcyla, licensed biologics, Oceanside, Penzberg, Perjeta, pertuzumab, RoACTEMRA, Roche, Switzerland, tocilizumab, trastuzumab emtansine, USA, Vacaville
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?